Search

The Finnish nanotechnology industry is in a boom phase, with the number of companies involved in the sector growing by 111 per cent in the past two years.

It’s easy to produce papers and make recommendations, says former Finnish prime minister Esko Aho. Now we need practical results.

YouTube, MySpace – those are some of the hottest properties on the Internet these days. They may also be the working definition of demand-side innovation,

European pharma and biotech companies are behind the US. But in one shining area, Europe has outpaced the US in creating a new sector: biosimilars.

The latest buzzword among Brussels technocrats is “lead markets”. And it’s going to be put into action, on an experimental basis, in 2007.

2006 was a record year for business start-ups in Ireland.

The value of R&D coming out of US universities is increasing. And the question of exactly how Europe measures up in comparison may soon be answered.

The band of UK quoted tech commercialisation companies has another member. Ipso Ventures joined the AIM market, raising £4.5 million.

Innovation policy is hot in Brussels, says Science|Business editor Richard L. Hudson. Hot enough for so a confusing array of proposals, white papers, conferences and task forces.

As it engages with global markets India’s self-interests in IP are shifting. The result is a surge in litigation as differences of opinion emerge within local companies, think tanks and advocacy groups.

A new and fast-growing sector of the private equity market aims to fund companies that put sustainability at their heart. A first survey of the field shows how.

Europe’s innovation skills are improving and closing the gap with the US and Japan. But the scoreboard shows European innovation is still only good in parts.

The European Commission said it will not raise any objections to the financial aid granted by France to a new transport programme.

Despite rumours of political roadblocks, the EU's education commissioner says a deal is in the works to create the European Institute of Technology.

The UK’s system for pricing drugs is to move from one based on controlling profits to a value-based approach. The switch has implications for other countries in Europe.

Venture capitalists are on a roll: in the past week two more firms confirmed the closing of significant new funds, to add to five others announced this year.